Post-SMR 2015 Congress: Advances in the Management of Metastatic Melanoma

http://academiccme.com/wp-content/uploads/2016/03/Screen-Shot-2016-03-21-at-12.14.05-PM-wpcf_400x400.png

Course Information

Therapautic Area: Oncology
Format(s): Downloadable Transcript , Slides/Audio, Post Conference Review and Analysis
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: January 16, 2016 - March 15, 2017

 

Program Overview

This CME activity will provide clinicians with a well-rounded review and analysis from the Society for Melanoma Research (SMR) 2015 Congress held in San Francisco, California. Due to the underlying molecular heterogeneity of metastatic melanoma, clinicians must appropriate test patients for genetic mutations that will shape therapeutic selection. Recent scientific data and the development of novel therapies have identified a need for educational activities focused on the management of patients with metastatic melanoma, which will be discussed in the program. This activity will provide learners with the most current information that will allow them to better treat and manage their metastatic melanoma patients and improve patient outcomes.

Target Audience

Oncologists, surgical oncologist/radiologists, dermatologists and other healthcare professionals responsible for the diagnosis, treatment or management of patients with melanoma.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Review the current clinical trial data for the treatment of metastatic melanoma as presented at Society of Melanoma Research 2015.
  2. Develop the most current treatment plans for patients with metastatic melanoma from data presented at Society of Melanoma Research 2015.

Faculty

Sznol Head ShotMario Sznol, MD
Professor of Internal Medicine
Co-Director
Yale SPORE in Skin Cancer
Translational Working Group Leader, Melanoma
New Haven, CT           

 

 

    

JeffrWeber Head Shotey S. Weber, MD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Lagone Medical Center
New York, NY

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Mario Sznol, MD  Consultant/Advisor: Astellas Pharma US, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Eli and Lily Company; Genentech, Inc.; Immune Design; Immunova LLC; Kyowa Hakko Kirin Pharma Inc.; Merus Labs Inc.; Nektar; Novartis AG; Pfizer, Inc.; Prometheus Laboratories Inc.; The Pierre Fabre Group
Jeffrey S. Weber, MD Consultant/Advisor: Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis AG;
Grant/Research Support: Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis AG

Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Genentech, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Genentech, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact admin@academiccme.com.
BUTTON